Loading news...
Campbell and CO Investment Adviser LLC lessened its holdings in Sotera Health Company (NASDAQ: SHC) by 34.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,382 shares of the company's stock after selling 33,128 shares during the quarter.
Shares of Sotera Health Company (NASDAQ: SHC - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy
Sotera Health Company (SHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CLEVELAND, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, is presenting today at the 44th Annual J.P. Morgan Healthcare Conference.
9,720,000 shares were sold indirectly for a transaction value of ~$158.7 million on Dec. 3, 2025. The sale represented 22.18% of total indirect holdings, reducing indirect exposure from 43,822,952 to 34,102,952 shares.
CLEVELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 p.m.
Sotera Health provides sterilization and lab testing services for the health care industry.
Sotera Health (NASDAQ: SHC - Get Free Report) and Surgery Partners (NASDAQ: SGRY - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Risk and Volatility Sotera Health has a
Sotera Health, a sterilization solutions provider, is gaining investor attention due to easing litigation and improving cash flow.
CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders.
Sotera Health Company ( SHC ) Q3 2025 Earnings Call November 4, 2025 9:00 AM EST Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - Senior VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Luke Sergott - Barclays Bank PLC, Research Division David Windley - Jefferies LLC, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Jason Bednar - Piper Sandler & Co., Research Division Michael Polark - Wolfe Research, LLC Presentation Operator Good morning, and welcome to the Sotera Health Third Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.
The headline numbers for Sotera Health (SHC) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago.
Q3 2025 net revenues increased 9.1% to $311 million , or 8.0% on a constant currency basis ( 1) , compared to Q3 2024 Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024 Q3 2025 Adjusted EBITDA ( 1 ) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024 Q3 2025 Adjusted EPS ( 1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024 Raising 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and reaffirming net revenues outlook range of 4.5% - 6.0%, on a constant currency basis CLEVELAND, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and nine-months ended September 30, 2025. Third-quarter 2025 net revenues increased 9.1% to $311 million, compared to $285 million in the third-quarter 2024.
Ethic Inc. lessened its position in shares of Sotera Health Company (NASDAQ: SHC) by 25.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,498 shares of the company's stock after selling 3,841 shares during the period. Ethic Inc.'s
CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m.
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.
Sotera Health Company (SHC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SHC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
While the top- and bottom-line numbers for Sotera Health (SHC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sotera Health Company (NASDAQ:SHC ) Q2 2025 Earnings Conference Call August 8, 2025 9:00 AM ET Company Participants Jason Peterson - VP & Treasurer Jonathan M. Lyons - Senior VP & CFO Michael B.